Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer’s Disease and Dementia with Lewy Bodies (DLB)

- End-of-Phase 2 Meeting with FDA for Mild-to-Moderate Alzheimer’s Disease Scheduled -

- Applications for IND and Breakthrough Status Filed for Dementia with Lewy Bodies -

Read more at globenewswire.com